We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Endo International PLC | NASDAQ:ENDP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.2926 | 0.29 | 0.294 | 0 | 01:00:00 |
As Filed with the Securities and Exchange Commission on August 5, 2019
Registration Statement No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Endo International plc
(Exact name of registrant as specified in its charter)
Ireland | 68-0683755 | |
(State or other jurisdiction of incorporation or organization) | (IRS Employer Identification No.) | |
First Floor, Minerva House, Simmonscourt Road, | ||
Ballsbridge, Dublin 4, Ireland | Not Applicable | |
(Address of principal executive offices) | (Zip Code) |
Endo International plc Amended and Restated 2015 Stock Incentive Plan
(Full Title of the Plan)
Matthew J. Maletta, Esq.
Executive Vice President, Chief Legal Officer
Endo International plc
1400 Atwater Drive
Malvern, Pennsylvania 19355
(484) 216-0000
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☒ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
|
||||||||
Title of securities
to be registered |
Amount to be
registered (1)(2) |
Proposed maximum
offering price per share (3) |
Proposed maximum
aggregate offering price (3) |
Amount of
registration fee |
||||
Ordinary shares, nominal value $0.0001 per share |
7,000,000 | $3.13 | $21,910,000.00 | $2,655.49 | ||||
|
||||||||
|
(1) |
This registration statement on Form S-8 (the Registration Statement ) registers the issuance of an aggregate of 7,000,000 ordinary shares, nominal value $0.0001 per share ( Ordinary Shares ), of Endo International plc (the Company or the Registrant ), that have been added to the award pool pursuant to the Endo International plc Amended and Restated 2015 Stock Incentive Plan, as further amended on June 11, 2019. |
(2) |
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the Securities Act ), this Registration Statement also covers an indeterminate number of additional Ordinary Shares of the Company which may be offered and issued to prevent dilution resulting from adjustments as a result of stock dividends, stock splits, reverse stock splits, recapitalizations, reclassifications, mergers, split-ups, reorganizations, consolidations and other capital adjustments. |
(3) |
Pursuant to Rules 457(c) and 457(h) under the Securities Act, the proposed maximum offering price per share and the proposed maximum aggregate offering are estimated solely for the purpose of calculating the amount of the registration fee and are based on the average of the high and low prices of the Companys Ordinary Shares as reported on the Nasdaq Global Market on July 29, 2019. Pursuant to Rule 457(h)(2) under the Securities Act, no separate fee is required to register plan interests. |
EXPLANATORY NOTE
This Registration Statement is filed pursuant to General Instruction E to Form S-8 for the purpose of registering an additional 7,000,000 Ordinary Shares of the Company that are reserved for future award grants pursuant to the Companys Amended and Restated 2015 Stock Incentive Plan (the Plan ), as amended and restated on June 11, 2019 (as in effect, the Amended Plan ).
On April 29, 2019, the Company filed its definitive proxy statement (the Proxy Statement ) with the Securities and Exchange Commission (the Commission ). Proposal 3 in the Proxy Statement requested that shareholders of the Company approve the Amended Plan, which, among other things, increases the authorized number of Ordinary Shares that may be issued under the Amended Plan by 7,000,000. On June 11, 2019, the shareholders of the Company approved the Amended Plan. The newly added 7,000,000 Ordinary Shares are being registered on this Registration Statement.
Previously, Ordinary Shares were registered for issuance under the Plan pursuant to the Registrants registration statements on Form S-8 filed on June 15, 2015 (File No. 333-204958), on August 9, 2017 (File No. 333-219806) and on August 8, 2018 (File No. 333-226677) (collectively, the Prior Registration Statements ). The Ordinary Shares registered pursuant to this Registration Statement are of the same class of securities as the Ordinary Shares registered pursuant to the Prior Registration Statements. In accordance with General Instruction E to Form S-8, the contents of the Prior Registration Statements, including any amendments thereto or filings incorporated therein, are incorporated herein by reference.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.
The following documents filed with the Commission are incorporated herein by reference (except for any portions of Current Reports on Form 8-K furnished pursuant to Item 2.02 or Item 7.01 thereof and any corresponding exhibits thereto not filed with the Commission):
(1) |
The Companys Registration Statements on Form S-8 (File No. 333-204958) filed on June 15, 2015 , Form S-8 (File No. 333-219806) filed on August 9, 2017 and Form S-8 (File No. 333-226677) filed on August 8, 2018 ; |
(2) |
The Companys Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed on February 28, 2019; |
(3) |
The Companys Quarterly Reports on Form 10-Q for the quarters ended March 31, 2019 and June 30, 2019, filed on May 9, 2019 and August 5, 2019 , respectively; |
(4) |
The Companys Current Reports on Form 8-K filed on March 14, 2019 , March 15, 2019 , March 28, 2019 , March 28, 2019 , April 26, 2019 , June 11, 2019 and June 28, 2019 ; |
(5) |
Those portions of the Companys Definitive Proxy Statement on Schedule 14A, filed on April 29, 2019, that are incorporated by reference into Part III of the Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed on February 28, 2019; and |
(6) |
The description of the Companys Ordinary Shares, contained in the Companys Registration Statement on Form S-3ASR , as amended (File No. 333-226676), under the heading Description of Share Capital. |
All documents that the Company files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act ), subsequent to the effective date of this Registration Statement (except for any portions of the Companys Current Reports on Form 8-K furnished pursuant to Item 2.02 or Item 7.01 thereof and any corresponding exhibits thereto not filed with Commission), but prior to the filing of a post-effective amendment to this Registration Statement indicating that all securities offered hereby have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing such documents.
Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
ITEM 8. EXHIBITS.
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Dublin, Ireland, on August 5, 2019.
ENDO INTERNATIONAL PLC | ||||
By: | /s/ Paul V. Campanelli | |||
Name: | Paul V. Campanelli | |||
Title: | President and Chief Executive Officer |
POWER OF ATTORNEY
BE IT KNOWN BY THESE PRESENTS: That each person whose name is signed hereto has made, constituted and appointed, and does hereby make, constitute and appoint Paul V. Campanelli, Blaise A. Coleman and Matthew J. Maletta his or her true and lawful attorney-in-fact and agent, each acting alone, with full power of substitution and resubstitution for him or her and his or her name, place and stead, in any and all capacities to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and the other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as they might or could do in person, hereby ratifying and confirming all that said attorney-in-fact or his substitutes, each acting alone, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
Title |
Date |
||
/s/ Paul V. Campanelli Paul V. Campanelli |
President, Chief Executive Officer and Director (principal executive officer) |
August 5, 2019 | ||
/s/ Blaise A. Coleman Blaise A. Coleman |
Executive Vice President and Chief Financial Officer (principal financial officer) |
August 5, 2019 | ||
/s/ Carrie A. Nichol Carrie A. Nichol |
Senior Vice President, Controller and Chief Accounting Officer (principal accounting officer) |
August 5, 2019 | ||
/s/ Roger H. Kimmel Roger H. Kimmel |
Chairman of the Board of Directors | August 5, 2019 | ||
/s/ Shane M. Cooke Shane M. Cooke |
Director | August 5, 2019 | ||
/s/ Nancy J. Hutson Nancy J. Hutson, Ph.D. |
Director | August 5, 2019 | ||
/s/ Michael Hyatt Michael Hyatt |
Director | August 5, 2019 | ||
/s/ Sharad S. Mansukani Sharad S. Mansukani, M.D. |
Director | August 5, 2019 | ||
/s/ William P. Montague William P. Montague |
Director | August 5, 2019 | ||
/s/ Matthew J. Maletta Matthew J. Maletta |
Authorized Representative in the United States | August 5, 2019 |
1 Year Endo Chart |
1 Month Endo Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions